Oramed Pharmaceuticals Inc. ORMP
4.03 USD -0.10 (-2.42%)
At closeNov 12, 2026, 4:00 PM EST
4.23 +0.20 +4.97%
After hours · Nov 12, 4:00 PM ET
3.94 Day range 4.22
2.25 52-week range 5.47
- YTD
- +41.40%
- 1 year
- +63.16%
News
defenseworld.net Oramed Pharmaceuticals (NASDAQ:ORMP) versus ProKidney (NASDAQ:PROK) Financial Comparison ProKidney (NASDAQ: PROK - Get Free Report) and Oramed Pharmaceuticals (NASDAQ: ORMP - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the…
defenseworld.net Contrasting Recursion Pharmaceuticals (NASDAQ:RXRX) & Oramed Pharmaceuticals (NASDAQ:ORMP) Oramed Pharmaceuticals (NASDAQ: ORMP - Get Free Report) and Recursion Pharmaceuticals (NASDAQ: RXRX - Get Free Report) are both healthcare companies, but which is the better business? We will…
defenseworld.net Contrasting Oramed Pharmaceuticals (NASDAQ:ORMP) and Generate Biomedicines (NASDAQ:GENB) Generate Biomedicines (NASDAQ: GENB - Get Free Report) and Oramed Pharmaceuticals (NASDAQ: ORMP - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will…
seekingalpha.com Oramed Pharmaceuticals: Hold Reiterated As Alpha Tau Investment Delivers And More Oramed Pharmaceuticals Inc. maintains a Hold rating as it pivots from drug development to strategic investments, with significant progress in asset growth and portfolio diversification. ORMP's…
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Atlantic International (NASDAQ:ATLN) shares increased by 41.0% to $1.1 during Thursday's regular session. The company's market cap stands at $59.4 million. As per the press release, Q1…
gurufocus.com Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation
prnewswire.com Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet Significant Appreciation in Alpha Tau (NASDAQ: DRTS) Position (up ~$128 Million) Scilex (NASDAQ: SCLX) Loan Substantially Repaid Total Cash and Assets Build to Approximately $270 Million (as of March…
prnewswire.com Oramed Pharmaceuticals to Join Russell 2000® and Russell 3000® Indexes NEW YORK, June 17, 2026 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), announced today that it is set to join the U.S. small cap Russell 2000® and…
seekingalpha.com Oramed Pharmaceuticals: 'Hold' On Oral Insulin Drug Failure Pivot And New Strategic Investment Direction Oramed Pharmaceuticals is downgraded from 'Strong Buy' to 'Hold' due to the failed phase 3 trial for ORMD-0801 in Type 2 Diabetes. ORMP pivots to target a subset of T2D patients and transfers its POD…
defenseworld.net Reviewing Oramed Pharmaceuticals (NASDAQ:ORMP) & Akanda (NASDAQ:AKAN) Akanda (NASDAQ: AKAN - Get Free Report) and Oramed Pharmaceuticals (NASDAQ: ORMP - Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two…
benzinga.com Lifeward Closes The Strategic Partnership Agreement With Oramed Pharmaceuticals Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced…
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session 
benzinga.com Lifeward Shareholders Approve Issuance Of Ordinary Shares Over Previously Announced Collaboration Deal With Oramed Pharmaceuticals Lifeward Ltd. (Nasdaq: LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today…
globenewswire.com Lifeward Receives Shareholder Approval to Close on Strategic Partnership with Oramed—Creating Diversified Biomedical Company Position s Lifeward as a diversified biomedical innovation company with clear path to profitability Integration of Oramed's POD™ oral delivery technology expands Lifeward into biotech markets while…
defenseworld.net Head to Head Review: GN Store Nord (OTCMKTS:GNNDY) and Oramed Pharmaceuticals (NASDAQ:ORMP) Oramed Pharmaceuticals (NASDAQ: ORMP - Get Free Report) and GN Store Nord (OTCMKTS:GNNDY - Get Free Report) are both medical companies, but which is the better business? We will compare the two…
defenseworld.net Oramed Pharmaceuticals (NASDAQ:ORMP) Stock Price Passes Above 50 Day Moving Average – Here’s Why Oramed Pharmaceuticals Inc. (NASDAQ: ORMP - Get Free Report)'s stock price passed above its 50-day moving average during trading on Monday. The stock has a 50-day moving average of $3.26 and traded…
defenseworld.net Comparing QuidelOrtho (NASDAQ:QDEL) & Oramed Pharmaceuticals (NASDAQ:ORMP) QuidelOrtho (NASDAQ: QDEL - Get Free Report) and Oramed Pharmaceuticals (NASDAQ: ORMP - Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the…
defenseworld.net Oramed Pharmaceuticals (NASDAQ:ORMP) Shares Pass Above Fifty Day Moving Average – Time to Sell? Oramed Pharmaceuticals Inc. (NASDAQ: ORMP - Get Free Report)'s stock price crossed above its 50-day moving average during trading on Monday. The stock has a 50-day moving average of $3.03 and traded…
benzinga.com Lifeward To Issue $10M In Senior Secured Convertible Notes In A Private Placement, Of Which Oramed To Invest $9M, And An Additional Milestone-Based $10M Senior Secured Convertible Note, Of Which Oramed Will Invest $9M, Each With 100% Warrant Coverage Transaction Will Transfer Oramed's Oral Drug Delivery Platform (POD™ Technology) to Lifeward and Positions Oramed as a Significant ShareholderOramed will transfer POD™ platform to Lifeward while
benzinga.com UPDATE: Lifeward To Acquire Oramed's POD Technology And Secure Up To $47M Strategic Investment As Oramed Takes Up To 49.99% Stake Transaction Will Transfer Oramed's Oral Drug Delivery Platform (POD™ Technology) to Lifeward and Positions Oramed as a Significant Shareholder
globenewswire.com Lifeward Enters Transformative Strategic Investment and Partnership Agreement with Oramed to Create a Diversified Biomedical Innovation Company Positions Lifeward as a MedTech platform with a clear path to cashflow positive and long-term Biotech upside potential Up to $47 million strategic investment from Oramed and another investor is…
prnewswire.com Oramed and Lifeward Announce Strategic Transaction Transaction Will Transfer Oramed's Oral Drug Delivery Platform (POD™ Technology) to Lifeward and Positions Oramed as a Significant Shareholder Oramed will transfer POD™ platform to Lifeward while…
benzinga.com Oramed Pharma Receives $18M Payment From Scilex Holdings, Representing $118M Total Returns On $99.5M Investment; Oramed Retains $39M Outstanding debt, Convertible Debt, Warrants, and Ongoing Royalty Interest Payment Closes Out Option Agreement Obligations; Oramed Retains $39 Million Outstanding debt, Convertible Debt, Warrants, and an Ongoing Royalty InterestNEW YORK, Jan. 7, 2026 /PRNewswire/ -- Oramed…
prnewswire.com Oramed Receives $18 Million Payment from Scilex Holdings, Bringing Current Returns to $118 Million; Board Approves Dividend Payments Payment Closes Out Option Agreement Obligations; Oramed Retains $39 Million Outstanding debt, Convertible Debt, Warrants, and an Ongoing Royalty Interest NEW YORK, Jan. 7, 2026 /PRNewswire/ -- Oramed…
defenseworld.net Reviewing Oramed Pharmaceuticals (NASDAQ:ORMP) & GE HealthCare Technologies (NASDAQ:GEHC) Oramed Pharmaceuticals (NASDAQ: ORMP - Get Free Report) and GE HealthCare Technologies (NASDAQ: GEHC - Get Free Report) are both medical companies, but which is the superior business? We will…
seekingalpha.com Oramed Pharmaceuticals: Scarred, Well-Capitalized, And Regrouping After Setback Oramed remains viable after its flagship product failed FDA trials three years ago. Management identified a responsive patient subset—elderly with low BMI and high baseline HbA1c—prompting a new…- benzinga.com Reported November 13, 2025: Oramed Pharmaceuticals Q3 EPS $1.26 Beats $(0.08) Estimate, Sales $2.000M Oramed Pharmaceuticals (NASDAQ:ORMP) reported quarterly earnings of $1.26 per share which beat the analyst consensus estimate of $(0.08) by 1675 percent. This is a 672.73 percent increase over losses…
prnewswire.com Oramed Reports Fiscal Third Quarter 2025 Financial Results Strong Nine-Month Performance Driven by Strategic Investment Portfolio; Total Assets Increase 42% to $220.5 Million NEW YORK , Nov. 17, 2025 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP)…- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
benzinga.com Oramed Grants Scilex $27M Option To Repurchase Warrants, With Potential Note Extension To 2026 As previously disclosed, on September 21, 2023, Oramed Pharmaceuticals Inc. (the "Company") entered into and consummated the transactions contemplated by a Securities Purchase Agreement (as amended…- benzinga.com Why Venus Concept Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session Gainers NeoGames S.A. (NASDAQ: NGMS) shares climbed 113.3% to $27.38 as the company agreed to be acquired by Aristocrat Leisure Limited for $29.50 per share in cash.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 29 stocks made new 52-week lows.
- benzinga.com Gold Tops $1,900 After US CPI Report, S&P 500 Rises 0.5% U.S. stocks traded higher toward the end of trading, following the release of inflation data.
- benzinga.com Why KNOT Offshore Partners Shares Are Trading Lower By Around 38%? Here Are Other Stocks Moving In Thursday's Mid-Day Session Gainers BigBear.ai Holdings, Inc. (NYSE: BBAI) shares jumped 239% to $2.8715 after the company announced it has been awarded a multiple award $900 million Indefinite Delivery/Indefinite Quantity…
- benzinga.com US Stocks Turn Higher; Dow Jumps 200 Points U.S. stocks turned higher midway through trading, following the release of inflation data.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 13 stocks hit new 52-week lows.
benzinga.com Dow Drops 150 Points; US Inflation Rate Slows In December U.S. stocks traded lower this morning, following the release of inflation data.
benzinga.com Why Akerna Shares Are Trading Higher By 97%; Here Are 20 Stocks Moving Premarket Gainers Akerna Corp. (NASDAQ: KERN) rose 97.4% to $1.91 in pre-market trading after the company reported the sale of 365 Cannabis for $2.8 million.- benzinga.com Oramed Pharmaceuticals, Logitech International And Some Other Big Stocks Moving Lower In Thursday's Pre-Market Session U.S. stock futures traded mixed this morning. Here are some big stocks recording losses in today’s pre-market trading session.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 807 companies reached new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 1043 companies hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday Wednesday's session saw 784 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday During Tuesday, 581 stocks hit new 52-week lows. Interesting Highlights From Today's 52-Week Lows Meta Platforms (NASDAQ:FB) was the biggest company on a market cap basis to set a new 52-week low.
- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 721 companies achieved new lows for the year.
- benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 431 companies hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 160 companies hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 466 companies hit new 52-week lows.
- benzinga.com 52 Biggest Movers From Yesterday Gainers ION Geophysical Corporation (NYSE: IO) shares surged 29.8% to settle at $0.5969.
benzinga.com 78 Biggest Movers From Friday Gainers PharmaCyte Biotech, Inc. (NASDAQ: PMCB) shares jumped 43.4% to close at $3.27. PharmaCyte Biotech recently reported closing of $15-million public offering.- benzinga.com Stocks That Hit 52-Week Highs On Tuesday Before 10 a.m. ET on Tuesday, 100 stocks hit new 52-week highs.